{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:33:54Z","timestamp":1791304434970,"version":"4.3.1"},"reference-count":70,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"HHS | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U19AI096398"],"award-info":[{"award-number":["U19AI096398"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000052","name":"HHS | NIH | NIH Office of the Director","doi-asserted-by":"publisher","award":["P51OD11132"],"award-info":[{"award-number":["P51OD11132"]}],"id":[{"id":"10.13039\/100000052","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The broadly neutralizing antibody (bNAb) VRC01, capable of neutralizing 91% of known human immunodeficiency virus type 1 (HIV-1) isolates\n            <jats:italic>in vitro<\/jats:italic>\n            , is a promising candidate microbicide for preventing sexual HIV infection when administered topically to the vagina; however, accessibility to antibody-based prophylactic treatment by target populations in sub-Saharan Africa and other underdeveloped regions may be limited by the high cost of conventionally produced antibodies and the limited capacity to manufacture such antibodies. Intravaginal rings of the pod design (pod-IVRs) delivering\n            <jats:named-content content-type=\"genus-species\">Nicotiana<\/jats:named-content>\n            -manufactured VRC01 (VRC01-N) over a range of release rates have been developed. The pharmacokinetics and preliminary safety of VRC01-N pod-IVRs were evaluated in a rhesus macaque model. The devices sustained VRC01-N release for up to 21 days at controlled rates, with mean steady-state VRC01-N levels in vaginal fluids in the range of 10\n            <jats:sup>2<\/jats:sup>\n            to 10\n            <jats:sup>3<\/jats:sup>\n            \u03bcg g\n            <jats:sup>\u22121<\/jats:sup>\n            being correlated with\n            <jats:italic>in vitro<\/jats:italic>\n            release rates. No adverse safety indications were observed. These findings indicate that pod-IVRs are promising devices for the delivery of the candidate topical microbicide VRC01-N against HIV-1 infection and merit further preclinical evaluation.\n          <\/jats:p>","DOI":"10.1128\/aac.02465-16","type":"journal-article","created":{"date-parts":[[2017,4,18]],"date-time":"2017-04-18T00:55:21Z","timestamp":1492476921000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":29,"title":["Pharmacokinetics and Preliminary Safety of Pod-Intravaginal Rings Delivering the Monoclonal Antibody VRC01-N for HIV Prophylaxis in a Macaque Model"],"prefix":"10.1128","volume":"61","author":[{"given":"Chunxia","family":"Zhao","sequence":"first","affiliation":[{"name":"Emory University School of Medicine, Atlanta, Georgia, USA"},{"name":"Yerkes National Primate Research Center, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjula","family":"Gunawardana","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Oak Crest Institute of Science, Monrovia, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Villinger","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine, Atlanta, Georgia, USA"},{"name":"Yerkes National Primate Research Center, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc M.","family":"Baum","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Oak Crest Institute of Science, Monrovia, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Remedios-Chan","sequence":"additional","affiliation":[{"name":"Auritec Pharmaceuticals, Inc., Pasadena, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Moench","sequence":"additional","affiliation":[{"name":"ReProtect, Inc., Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Zeitlin","sequence":"additional","affiliation":[{"name":"Mapp Biopharmaceutical Inc., San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J.","family":"Whaley","sequence":"additional","affiliation":[{"name":"Mapp Biopharmaceutical Inc., San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ognian","family":"Bohorov","sequence":"additional","affiliation":[{"name":"Mapp Biopharmaceutical Inc., San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Smith","sequence":"additional","affiliation":[{"name":"Auritec Pharmaceuticals, Inc., Pasadena, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah J.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Departments of Obstetrics\/Gynecology, Microbiology, and Medicine, Boston University School of Medicine, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Moss","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Oak Crest Institute of Science, Monrovia, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61255-X"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1206399"},{"key":"e_1_3_3_4_2","volume-title":"Report on the global AIDS epidemic","author":"Joint United Nations Programme on HIV\/AIDS","year":"2013","unstructured":"Joint United Nations Programme on HIV\/AIDS. 2013. Report on the global AIDS epidemic. Joint United Nations Programme on HIV\/AIDS, Geneva, Switzerland. http:\/\/www.unaids.org\/en\/resources\/publications\/2013. Accessed 3 November 2016."},{"key":"e_1_3_3_5_2","volume-title":"AIDS by the numbers","author":"Joint United Nations Programme on HIV\/AIDS","year":"2016","unstructured":"Joint United Nations Programme on HIV\/AIDS. 2016. AIDS by the numbers. Joint United Nations Programme on HIV\/AIDS, Geneva, Switzerland. http:\/\/www.unaids.org\/en\/resources\/documents\/2016\/AIDS-by-the-numbers. Accessed 3 November 2016."},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1108524"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506110"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011205"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1193748"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110711"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402269"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1202614"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12075"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg172"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.23.13232-13252.2004"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.7973652"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature05580"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1083182"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.69.11.6609-6617.1995"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.67.11.6642-6647.1993"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.22.10892-10905.2001"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/72309"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01272-09"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1103012108"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm833"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0116153"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/632893"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0008805"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature10373"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1187659"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063537"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12692"},{"key":"e_1_3_3_33_2","volume-title":"Evaluating the safety and efficacy of the VRC01 antibody in reducing acquisition of HIV-1 infection in women","author":"National Institute of Allergy and Infectious Diseases","year":"2015","unstructured":"National Institute of Allergy and Infectious Diseases. 2015. Evaluating the safety and efficacy of the VRC01 antibody in reducing acquisition of HIV-1 infection in women. National Library of Medicine, Bethesda, MD. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02568215."},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2012.06.025"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2013.23"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008992"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01748-14"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-7652.2007.00306.x"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0708841104"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-7652.2008.00330.x"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.09-131771"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/pbi.12137"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02588-12"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2015.09.028"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.23208"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.24154"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1095\/biolreprod47.1.133"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2010.10.010"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02871-14"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0684.2009.00354.x"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature08757"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0023136"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055013"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00991-10"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1286-4579(02)00056-4"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01198-12"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00976-10"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20131244"},{"key":"e_1_3_3_59_2","unstructured":"LeafBio Inc. 2015. Vaginal Antibody Safety Trial: safety study of monoclonal antibodies to reduce the vaginal transmission of herpes simplex virus (HSV) and human immunodeficiency virus (HIV) (VAST). National Library of Medicine Bethesda MD. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02579083."},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2010.09.003"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2013.09.027"},{"key":"e_1_3_3_62_2","volume-title":"Final report","author":"Center for Biosecurity of UPMC","year":"2013","unstructured":"Center for Biosecurity of UPMC. 2013. Next-generation monoclonal antibodies: challenges and opportunities. Final report. Center for Biosecurity of UPMC, Washington, DC."},{"key":"e_1_3_3_63_2","first-page":"995","article-title":"Very large scale monoclonal antibody purification: the case for conventional unit operations","volume":"23","author":"Kelley B","year":"2007","unstructured":"Kelley B . 2007. Very large scale monoclonal antibody purification: the case for conventional unit operations. Biotechnol Prog23:995\u20131008.","journal-title":"Biotechnol Prog"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2006.07.037"},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.1007\/82_2012_240"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.4161\/hv.7.3.14266"},{"key":"e_1_3_3_67_2","first-page":"39","volume-title":"The bridge","author":"Estelle D","year":"2006","unstructured":"Estelle D . 2006. Adapting industry practices for the rapid, large-scale manufacture of pharmaceutical proteins, p 39\u201344. InThe bridge. National Academy of Engineering, Washington, DC."},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-7824(99)00010-4"},{"key":"e_1_3_3_69_2","volume-title":"Guide for the care and use of laboratory animals","author":"National Research Council","year":"2011","unstructured":"National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC. https:\/\/grants.nih.gov\/grants\/olaw\/guide-for-the-care-and-use-of-laboratory-animals.pdf.","edition":"8"},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2008.01.040"},{"key":"e_1_3_3_71_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157061"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02465-16","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02465-16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:06:20Z","timestamp":1645477580000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02465-16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":70,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["10.1128\/AAC.02465-16"],"URL":"https:\/\/doi.org\/10.1128\/aac.02465-16","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"2016-11-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-04-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-06-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02465-16"}}